Martin H. Huber Jr.

CIK: 0001653276

Transaction Breakdown

Open Market Buys (P)1 (3.2%)

High conviction signal

Open Market Sales (S)3 (9.7%)

Position reduction

Option Exercises (M)3 (9.7%)

Derivative conversions

Awards (A)5 (16.1%)

Compensation grants

Other (G, F, J, C, D, …)19 (61.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

ACTU

ACTUATE THERAPEUTICS, INC.

Director

SNDX

Syndax Pharmaceuticals Inc

Director

MRSN

Mersana Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (31 total)

ACTU
ACTUATE THERAPEUTICS, INC.
May 21, 2026
Award(A)
Stock Options
Direct
15K shares-
SNDX
Syndax Pharmaceuticals Inc
Feb 4, 2026
Award(A)
Direct
24K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Restricted Stock Units
Direct
7.3K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
135 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
734 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
179 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
12.1K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
27.9K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
364 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
497 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
7.5K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Restricted Stock Units
Direct
13.3K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Restricted Stock Units
Direct
1.3K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Tender Offer(U)
Direct
9.6K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
5.9K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
26.7K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
1.9K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
99 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
1K shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
407 shares-
MRSN
Mersana Therapeutics, Inc.
Jan 6, 2026
Disposition(D)
Stock Option (right to buy)
Direct
1.8K shares-
MRSN
Mersana Therapeutics, Inc.
Sep 12, 2025
Sale(S)
Direct
2K shares at avg. $7.31$15K
MRSN
Mersana Therapeutics, Inc.
Sep 11, 2025
Exercise(M)
Direct
6.7K shares-
SNDX
Syndax Pharmaceuticals Inc
May 19, 2025
Purchase(P)
Direct
5K shares at avg. $8.99$45K
SNDX
Syndax Pharmaceuticals Inc
Feb 5, 2025
Award(A)
Direct
25K shares-

		Type	Shares	Price		Ownership
May 21, 2026	ACTU ACTUATE THERAPEUTICS, INC.	Award(A) Stock Options	15,000	-	-	Direct
Feb 4, 2026	SNDX Syndax Pharmaceuticals Inc	Award(A)	24,000	-	$0	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Restricted Stock Units	7,256	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	135	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	734	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	179	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	12,121	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	27,878	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	364	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	497	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	7,467	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Restricted Stock Units	13,340	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Restricted Stock Units	1,328	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Tender Offer(U)	9,573	-	$0	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	5,938	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	26,713	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	1,923	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	99	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	1,002	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	407	-	-	Direct
Jan 6, 2026	MRSN Mersana Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	1,800	-	-	Direct
Sep 12, 2025	MRSN Mersana Therapeutics, Inc.	Sale(S)	2,012	$7.31	$14,708	Direct
Sep 11, 2025	MRSN Mersana Therapeutics, Inc.	Exercise(M)	6,670	-	-	Direct
May 19, 2025	SNDX Syndax Pharmaceuticals Inc	Purchase(P)	5,000	$8.99	$44,950	Direct
Feb 5, 2025	SNDX Syndax Pharmaceuticals Inc	Award(A)	25,000	-	-	Direct

1-25 of 31 transactions

About Huber Martin H. Jr.

Huber Martin H. Jr. (SEC CIK 0001653276) files insider reports with the SEC as Director of ACTUATE THERAPEUTICS, INC. (ACTU), Director of Syndax Pharmaceuticals Inc (SNDX) and President, CEO of Mersana Therapeutics, Inc. (MRSN).

Signal8 holds 9 ownership filings by Huber Martin H. Jr. (1 Form 3, 8 Form 4), filed between Sep 13, 2024 and May 22, 2026. Those filings report 31 transactions, from Sep 11, 2024 to May 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Huber Martin H. Jr.'s filings is in NEW YORK, NY.

Recent filings by Huber Martin H. Jr.

May 21, 2026: Grant or award of ACTU derivative securities (Form 4, code A).
Feb 4, 2026: Grant or award of SNDX shares (Form 4, code A).
Jan 6, 2026: Disposition to issuer transactions of MRSN derivative securities (11 lines, Form 4, code D).
Jan 6, 2026: Tender of shares transaction of MRSN shares (Form 4, code U).
Jan 6, 2026: Disposition to issuer transactions of MRSN derivative securities (7 lines, Form 4, code D).

Other insiders filing for ACTUATE THERAPEUTICS, INC. (ACTU)

THOMSON TODD S, Director
BIOS Fund III, LP, Director
BIOS Fund I, LP, Director
SCHMITT DANIEL M, President, CEO and Director
Zabrowski Dan, Director
Sawhney Roger, Director

How to read Form 4 transaction codes